federal_register: 2016-29998

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present. Nearly 1M documents with full-text search.

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts
2016-29998 Public Meeting on Patient-Focused Drug Development for Sarcopenia; Request for Comments Notice The Food and Drug Administration (FDA or Agency) is announcing a public meeting and an opportunity for public comment on "Patient- Focused Drug Development for Sarcopenia." Patient-Focused Drug Development is part of FDA's performance commitments made as part of the fifth authorization of the Prescription Drug User Fee Act (PDUFA V). The public meeting is intended to allow FDA to obtain patient perspectives on the impact of sarcopenia on daily life as well as patient views on treatment approaches for sarcopenia. 2016-12-14 2016 12 https://www.federalregister.gov/documents/2016/12/14/2016-29998/public-meeting-on-patient-focused-drug-development-for-sarcopenia-request-for-comments https://www.govinfo.gov/content/pkg/FR-2016-12-14/pdf/2016-29998.pdf Health and Human Services Department; Food and Drug Administration 221,199 The Food and Drug Administration (FDA or Agency) is announcing a public meeting and an opportunity for public comment on "Patient- Focused Drug Development for Sarcopenia." Patient-Focused Drug Development is part of FDA's performance commitments made...

Links from other tables